

Notice of Allowability

Application No.

10/614,954

Applicant(s)

HOHN ET AL

Examiner

Medina A. Ibrahim

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment of 05/09/05.
2. ☒ The allowed claim(s) is/are 1-5.
3. ☒ The drawings filed on 07 July 2003 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____. |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other ____. |

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Gregory Warren on 06/25/05.

The application has been amended as follows:

In The Title:

The title has been replaced with the following:

--- ISOLATED NUCLEIC ACIDS ENCODING TRICHOTHECENE 3-O-
ACETYLTRANSFERASES ----.

In The Abstract:

The abstract has been replaced with the following:

---- The present invention discloses isolated polynucleotides encoding polypeptides having trichothecene 3-O-acetyltransferase activity, recombinant vectors and host cell comprising said polynucleotides-----.

In The claims:

In claims 3-5, "gene" has been replaced with ---DNA----.

Reasons for allowance

The following is an examiner's statement of reasons for allowance: the prior art does not teach or reasonably suggest a nucleotide sequence that is 100% identical to

Art Unit: 1638

SEQ ID NO: 5 or a nucleotide sequence encoding SEQ ID NO: 6. The closest prior art is Kimura et al (J. Biol. Chem. (1998), 273 (3): 1654-1661, Applicant's IDS) who teach a nucleotide sequence having 99% sequence identity with Applicant's SEQ ID NO: 5. See attached sequence alignment results (Exhibit A/B) between SEQ ID NO: 5/6 and the prior art sequences.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Contact information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571) 272-0797. The Examiner can normally be reached Monday -Thursday from 8:00AM to 5:30PM and every other Friday from 9:00AM to 5:00 PM. Before and after final responses should be directed to fax nos. (703) 872-9306 and (703) 872-9307, respectively.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Amy Nelson, can be reached at (571) 272-0804.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

6/25/05

Mai

MEDINA A. IBRAHIM
PATENT EXAMINER

Medina A. Ibrahim
1638

06 May 2005

Alignment Results

Alignment: Global DNA alignment against reference molecule
 Parameters: Scoring matrix: Linear (Mismatch 2, OpenGap 4, ExtGap 1)

Reference molecule: SEQIDNO:5, Region 1-1356
 Number of sequences to align: 2
 Settings: Similarity significance value cutoff: >= 60%



Summary of Percent Matches:

Reference:	SEQIDNO:5	1 - 1356	(1356 bps)	--
Sequence 2:	Kimura Tri101	135 - 1490	(1356 bps)	99%

SEQIDNO:5	1	atggctttcaagatacagctcgacaccctcgccagctaccaggcctcctttcgatctac
Kimura Tri10	135	atggctttcaagatacagctcgacaccctcgccagctaccaggcctcctttcgatctac
SEQIDNO:5	61	acccaaatcagtcctctaccccgctctctgattcctctcaatatccactattgtcagc
Kimura Tri10	195	acccaaatcagtcctctaccccgctctctgattcctctcaatatccactattgtcagc
SEQIDNO:5	121	accttcgagcaaggctctaagcgcttctccgaagccgctcccatgggtcgagccagggtc
Kimura Tri10	255	accttcgagcaaggctctaagcgcttctccgaagccgctcccatgggtcgagccagggtc
SEQIDNO:5	181	aaagccgagggcattagcgagggaaacacaggaacttcctttatcgctcccttttgaggac
Kimura Tri10	315	aaagccgagggcattagcgagggaaacacaggaacttcctttatcgctcccttttgaggac
SEQIDNO:5	241	gttcctcgtgttgtagtgaagacctccgcgatgatccttcagcgccacgatcgaggggt
Kimura Tri10	375	gttcctcgtgttgtagtgaagacctccgcgatgatccttcagcgccacgatcgaggggt
SEQIDNO:5	301	atgagaaaggcgggataccctatggcgatgtttgacgagaacatcatcgcgccaaggaag
Kimura Tri10	435	atgagaaaggcgggataccctatggcgatgtttgacgagaacatcatcgcgccaaggaag
SEQIDNO:5	361	acgttacctattggacctggtactgggtcccgacgacccaaagcctgtgaattctattgcag
Kimura Tri10	495	acgttacctattggacctggtactgggtcccgacgacccaaagcctgtgaattctattgcag
SEQIDNO:5	421	ctcaacttcataagggcggtactcctcactgtcaacggacagcacgggtgctatggat
Kimura Tri10	555	ctcaacttcataagggcggtactcctcactgtcaacggacagcacgggtgctatggat
SEQIDNO:5	481	atggtaggccaagatgcggtgatccgtctactctccaaggcgtgcccgaacgacccattc
Kimura Tri10	615	atggtaggccaagatgcggtgatccgtctactctccaaggcgtgcccgaacgacccattc
SEQIDNO:5	541	accgaagaggaaatgacggccatgaacctcgatcgcaagacgatagttccttaccttgaa
Kimura Tri10	675	accgaagaggaaatgacggccatgaacctcgatcgcaagacgatagttccttaccttgaa
SEQIDNO:5	601	aactatacgattggccccgaggtagatcatcagattgtcaaagctgatgtagctggtggt
Kimura Tri10	735	aactatacgattggccccgaggtagatcatcagattgtcaaagctgatgtagctggtggt
SEQIDNO:5	661	gacgctgttctcagcgccgtcagtgcaagctgggcgttcttcacattcagccccaaaggcc
Kimura Tri10	795	gacgctgttctcagcgccgtcagtgcaagctgggcgttcttcacattcagccccaaaggcc
SEQIDNO:5	721	atgtcagagctcaaggatgctgctaccaagactcttgacgcatacaaaaagttcgtgtcg
Kimura Tri10	855	atgtcagagctcaaggatgctgctaccaagactcttgacgcatacaaaaagttcgtgtcg
SEQIDNO:5	781	actgacgatgctcttttcggcggttcactctggaatcgccctctcgcggtgctctcgaaaga
Kimura Tri10	915	actgacgatgctcttttcggcggttcactctggaatcgccctctcgcggtgctctcgaaaga
SEQIDNO:5	841	atcgatggctctgcacctaccgagttctgcccgtgctgttgatgctcgaccggcaatgggt
Kimura Tri10	975	atcgatggctctgcacctaccgagttctgcccgtgctgttgatgctcgaccggcaatgggt
SEQIDNO:5	901	gtctcgaacaactaccaggccttcttcaaaacatgacctaccacaactcgaccatcggc
Kimura Tri10	1035	gtctcgaacaactaccaggccttcttcaaaacatgacctaccacaactcgaccatcggc
SEQIDNO:5	961	gaaatcgccaacgagtcactcgggcgcaacagcatcacgccttcggttcagaactcgacccc
Kimura Tri10	1095	gaaatcgccaacgagtcactcgggcgcaacagcatcacgccttcggttcagaactcgacccc

SEQIDNO:5 1021 gcgagcatgcgccagcgaacaagaggtctcgcgacgtacctgcacaacaaccccgacaag
Kimura Tri10 1155 gcgagcatgcgccagcgaacaagaggtctcgcgacgtacctgcacaacaaccccgacaag

SEQIDNO:5 1081 tccaacgtatccctgacggctgatgcggacccatctaccagcgtcatgctgagttcttgg
Kimura Tri10 1215 tccaacgtatctctgacggctgatgcggacccatctaccagcgtcatgctgagttcttgg

SEQIDNO:5 1141 gccaaggtgggactctgggattacgactttgggctcggactgggtaagcccagactgtg
Kimura Tri10 1275 gccaaggtcggactctgggattacgactttgggttcggactgggtaagcccagactgtg

SEQIDNO:5 1201 agacggccaatctttgagcctgttgagagcttgatgtactttatgcccaagaagcctgat
Kimura Tri10 1335 agacggccaatctttgagcctgttgagagcttgatgtactttatgcccaagaagcctgat

SEQIDNO:5 1261 ggcgagttctgtgcggcgctttctctgagggatgaggatatggaccgattgaaggcggat
Kimura Tri10 1395 ggcgagttctgtgcggcgctttctctgagggatgaggatatggaccgattgaaggcggat

SEQIDNO:5 1321 aaggagtggaccaagtatgcgcagtagcgttggttag
Kimura Tri10 1455 aaggagtggaccaagtatgcgcagtagcgttggttag

06 May 2005

Alignment Results

Exhibit B

Alignment: Global Protein alignment against reference molecule
Parameters: Scoring matrix: BLOSUM 62

Reference molecule: SEQIDNO:6, Region 1-451

Number of sequences to align: 2

Settings: Similarity significance value cutoff: >= 60%



Summary of Percent Matches:

Reference:	SEQIDNO:6	1 - 451 (451 aa)	--
Sequence 2:	Kimura Tri101 Pro	1 - 451 (451 aa)	99%

SEQIDNO:6	1	<u>mafkiqldtlgqlpgllsiytqisllypvsdssqyptivstfeqglkrfseavpwvagqv</u>
Kimura Tri10	1	<u>mafkiqldtlgqlpgllsiytqisllypvsdpsqyptivstfeqglkrfseavpwvagqv</u>
SEQIDNO:6	61	<u>kaegisegntgtsfiivpfedvprvvvkdldrddpsaptiegmrkagypmamfdeniapr</u>
Kimura Tri10	61	<u>kaegisegntgtsfiivpfedvprvvvkdldrddpsaptiegmrkagypmamfdeniapr</u>
SEQIDNO:6	121	<u>tlpigpgtgpdcpkvillqlnfikggllltvngqhgamdmggdavirllskacrndpf</u>
Kimura Tri10	121	<u>tlpigpgtgpdcpkvillqlnfikggllltvngqhgamdmggdavirllskacrndpf</u>
SEQIDNO:6	181	<u>teeemtamnlrktivpylenytigpevdhqvkdavaggdavltpvsaswafftfspka</u>
Kimura Tri10	181	<u>teeemtamnlrktivpylenytigpevdhqvkdavaggdavltpvsaswaffkfspka</u>
SEQIDNO:6	241	<u>mselkdaatktldastkfystddalsafiwksasrvrleridgsaptefcravdarpamg</u>
Kimura Tri10	241	<u>mselkdaatktldastkfystddalsafiwksasrvrleridgsaptefcravdarpamg</u>
SEQIDNO:6	301	<u>vsnnypgllqnmtyhnstigeianeslgatasrlrseldpasmrqrtrglatylhnnpd</u>
Kimura Tri10	301	<u>vsnnypgllqnmtyhnstigeianeslgatasrlrseldpasmrqrtrglatylhnnpd</u>
SEQIDNO:6	361	<u>snvsltadadpstsvmlsswakvglwdydfgfglgkpetvrrpifepveslmyfmpk</u>
Kimura Tri10	361	<u>snvsltadadpstsvmlsswakvglwdydfgfglgkpetvrrpifepveslmyfmpk</u>
SEQIDNO:6	421	<u>gefcaalslrddedmdrlkadkewtkyaqyv</u>
Kimura Tri10	421	<u>gefcaalslrddedmdrlkadkewtkyaqyv</u>